Structures, functions, and inhibitors of LUBAC and its related diseases
Ubiquitination is a reversible posttranslational modification in which ubiquitin is covalently attached to substrates at catalysis by E1, E2, and E3 enzymes. As the only E3 ligase for assembling linear ubiquitin chains in animals, the LUBAC complex exerts an essential role in the wide variety of cel...
Gespeichert in:
Veröffentlicht in: | Journal of leukocyte biology 2022-10, Vol.112 (4), p.799-811 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 811 |
---|---|
container_issue | 4 |
container_start_page | 799 |
container_title | Journal of leukocyte biology |
container_volume | 112 |
creator | Ning, Shuo Luo, Lingling Yu, Beiming Mai, Dina Wang, Feng |
description | Ubiquitination is a reversible posttranslational modification in which ubiquitin is covalently attached to substrates at catalysis by E1, E2, and E3 enzymes. As the only E3 ligase for assembling linear ubiquitin chains in animals, the LUBAC complex exerts an essential role in the wide variety of cellular activities. Recent advances in the LUBAC complex, including structure, physiology, and correlation with malignant diseases, have enabled the discovery of potent inhibitors to treat immune‐related diseases and cancer brought by LUBAC complex dysfunction. In this review, we summarize the current progress on the structures, physiologic functions, inhibitors of LUBAC, and its potential role in immune diseases, tumors, and other diseases, providing the theoretical basis for therapy of related diseases targeting the LUBAC complex.
Graphical
Review on the structures, physiological functions, inhibitors of LUBAC, and related diseases caused by LUBAC aberration, providing comprehensively insight into LUBAC research. |
doi_str_mv | 10.1002/JLB.3MR0222-508R |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2638013963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638013963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3463-7f588f28eedd7bbb42847b8f1e2cdb8c0f5c2f184960164b8310ad9a0f1456203</originalsourceid><addsrcrecordid>eNqFkD1PwzAURS0EoqWwM6GMDASeP-I4Y1tBAQUhFTpbdmwLozQpdiLUf0-qFlam93R17h0OQpcYbjEAuXsuZ7f0ZQmEkDQDsTxCY1xQkVKe02M0hpzhNGMAI3QW4ycAUMLhFI1oRjjHBYzR4q0LfdX1wcabxPVN1fm2GV7VmMQ3H177rg0xaV1SrmbT-T7vYhJsrTprEuOjVdHGc3TiVB3txeFO0Orh_n3-mJavi6f5tEwryjhNc5cJ4Yiw1phca82IYLkWDltSGS0qcFlFHBas4IA504JiUKZQ4DDLOAE6Qdf73U1ov3obO7n2sbJ1rRrb9lESTgVgWnA6oLBHq9DGGKyTm-DXKmwlBrnTJwd98qBP7vQNlavDeq_X1vwVfn0NAN8D3762238HdwHGGCj9ARqSegM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638013963</pqid></control><display><type>article</type><title>Structures, functions, and inhibitors of LUBAC and its related diseases</title><source>Access via Wiley Online Library</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Ning, Shuo ; Luo, Lingling ; Yu, Beiming ; Mai, Dina ; Wang, Feng</creator><creatorcontrib>Ning, Shuo ; Luo, Lingling ; Yu, Beiming ; Mai, Dina ; Wang, Feng</creatorcontrib><description>Ubiquitination is a reversible posttranslational modification in which ubiquitin is covalently attached to substrates at catalysis by E1, E2, and E3 enzymes. As the only E3 ligase for assembling linear ubiquitin chains in animals, the LUBAC complex exerts an essential role in the wide variety of cellular activities. Recent advances in the LUBAC complex, including structure, physiology, and correlation with malignant diseases, have enabled the discovery of potent inhibitors to treat immune‐related diseases and cancer brought by LUBAC complex dysfunction. In this review, we summarize the current progress on the structures, physiologic functions, inhibitors of LUBAC, and its potential role in immune diseases, tumors, and other diseases, providing the theoretical basis for therapy of related diseases targeting the LUBAC complex.
Graphical
Review on the structures, physiological functions, inhibitors of LUBAC, and related diseases caused by LUBAC aberration, providing comprehensively insight into LUBAC research.</description><identifier>ISSN: 0741-5400</identifier><identifier>EISSN: 1938-3673</identifier><identifier>DOI: 10.1002/JLB.3MR0222-508R</identifier><identifier>PMID: 35266190</identifier><language>eng</language><publisher>United States</publisher><subject>inhibitors ; linear ubiquitin chains ; LUBAC ; LUBAC‐associated DUBs ; structure</subject><ispartof>Journal of leukocyte biology, 2022-10, Vol.112 (4), p.799-811</ispartof><rights>2022 Society for Leukocyte Biology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3463-7f588f28eedd7bbb42847b8f1e2cdb8c0f5c2f184960164b8310ad9a0f1456203</citedby><cites>FETCH-LOGICAL-c3463-7f588f28eedd7bbb42847b8f1e2cdb8c0f5c2f184960164b8310ad9a0f1456203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2FJLB.3MR0222-508R$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2FJLB.3MR0222-508R$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35266190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ning, Shuo</creatorcontrib><creatorcontrib>Luo, Lingling</creatorcontrib><creatorcontrib>Yu, Beiming</creatorcontrib><creatorcontrib>Mai, Dina</creatorcontrib><creatorcontrib>Wang, Feng</creatorcontrib><title>Structures, functions, and inhibitors of LUBAC and its related diseases</title><title>Journal of leukocyte biology</title><addtitle>J Leukoc Biol</addtitle><description>Ubiquitination is a reversible posttranslational modification in which ubiquitin is covalently attached to substrates at catalysis by E1, E2, and E3 enzymes. As the only E3 ligase for assembling linear ubiquitin chains in animals, the LUBAC complex exerts an essential role in the wide variety of cellular activities. Recent advances in the LUBAC complex, including structure, physiology, and correlation with malignant diseases, have enabled the discovery of potent inhibitors to treat immune‐related diseases and cancer brought by LUBAC complex dysfunction. In this review, we summarize the current progress on the structures, physiologic functions, inhibitors of LUBAC, and its potential role in immune diseases, tumors, and other diseases, providing the theoretical basis for therapy of related diseases targeting the LUBAC complex.
Graphical
Review on the structures, physiological functions, inhibitors of LUBAC, and related diseases caused by LUBAC aberration, providing comprehensively insight into LUBAC research.</description><subject>inhibitors</subject><subject>linear ubiquitin chains</subject><subject>LUBAC</subject><subject>LUBAC‐associated DUBs</subject><subject>structure</subject><issn>0741-5400</issn><issn>1938-3673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkD1PwzAURS0EoqWwM6GMDASeP-I4Y1tBAQUhFTpbdmwLozQpdiLUf0-qFlam93R17h0OQpcYbjEAuXsuZ7f0ZQmEkDQDsTxCY1xQkVKe02M0hpzhNGMAI3QW4ycAUMLhFI1oRjjHBYzR4q0LfdX1wcabxPVN1fm2GV7VmMQ3H177rg0xaV1SrmbT-T7vYhJsrTprEuOjVdHGc3TiVB3txeFO0Orh_n3-mJavi6f5tEwryjhNc5cJ4Yiw1phca82IYLkWDltSGS0qcFlFHBas4IA504JiUKZQ4DDLOAE6Qdf73U1ov3obO7n2sbJ1rRrb9lESTgVgWnA6oLBHq9DGGKyTm-DXKmwlBrnTJwd98qBP7vQNlavDeq_X1vwVfn0NAN8D3762238HdwHGGCj9ARqSegM</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Ning, Shuo</creator><creator>Luo, Lingling</creator><creator>Yu, Beiming</creator><creator>Mai, Dina</creator><creator>Wang, Feng</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202210</creationdate><title>Structures, functions, and inhibitors of LUBAC and its related diseases</title><author>Ning, Shuo ; Luo, Lingling ; Yu, Beiming ; Mai, Dina ; Wang, Feng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3463-7f588f28eedd7bbb42847b8f1e2cdb8c0f5c2f184960164b8310ad9a0f1456203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>inhibitors</topic><topic>linear ubiquitin chains</topic><topic>LUBAC</topic><topic>LUBAC‐associated DUBs</topic><topic>structure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ning, Shuo</creatorcontrib><creatorcontrib>Luo, Lingling</creatorcontrib><creatorcontrib>Yu, Beiming</creatorcontrib><creatorcontrib>Mai, Dina</creatorcontrib><creatorcontrib>Wang, Feng</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of leukocyte biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ning, Shuo</au><au>Luo, Lingling</au><au>Yu, Beiming</au><au>Mai, Dina</au><au>Wang, Feng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structures, functions, and inhibitors of LUBAC and its related diseases</atitle><jtitle>Journal of leukocyte biology</jtitle><addtitle>J Leukoc Biol</addtitle><date>2022-10</date><risdate>2022</risdate><volume>112</volume><issue>4</issue><spage>799</spage><epage>811</epage><pages>799-811</pages><issn>0741-5400</issn><eissn>1938-3673</eissn><abstract>Ubiquitination is a reversible posttranslational modification in which ubiquitin is covalently attached to substrates at catalysis by E1, E2, and E3 enzymes. As the only E3 ligase for assembling linear ubiquitin chains in animals, the LUBAC complex exerts an essential role in the wide variety of cellular activities. Recent advances in the LUBAC complex, including structure, physiology, and correlation with malignant diseases, have enabled the discovery of potent inhibitors to treat immune‐related diseases and cancer brought by LUBAC complex dysfunction. In this review, we summarize the current progress on the structures, physiologic functions, inhibitors of LUBAC, and its potential role in immune diseases, tumors, and other diseases, providing the theoretical basis for therapy of related diseases targeting the LUBAC complex.
Graphical
Review on the structures, physiological functions, inhibitors of LUBAC, and related diseases caused by LUBAC aberration, providing comprehensively insight into LUBAC research.</abstract><cop>United States</cop><pmid>35266190</pmid><doi>10.1002/JLB.3MR0222-508R</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0741-5400 |
ispartof | Journal of leukocyte biology, 2022-10, Vol.112 (4), p.799-811 |
issn | 0741-5400 1938-3673 |
language | eng |
recordid | cdi_proquest_miscellaneous_2638013963 |
source | Access via Wiley Online Library; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | inhibitors linear ubiquitin chains LUBAC LUBAC‐associated DUBs structure |
title | Structures, functions, and inhibitors of LUBAC and its related diseases |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T13%3A01%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structures,%20functions,%20and%20inhibitors%20of%20LUBAC%20and%20its%20related%20diseases&rft.jtitle=Journal%20of%20leukocyte%20biology&rft.au=Ning,%20Shuo&rft.date=2022-10&rft.volume=112&rft.issue=4&rft.spage=799&rft.epage=811&rft.pages=799-811&rft.issn=0741-5400&rft.eissn=1938-3673&rft_id=info:doi/10.1002/JLB.3MR0222-508R&rft_dat=%3Cproquest_cross%3E2638013963%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638013963&rft_id=info:pmid/35266190&rfr_iscdi=true |